Navigation Links
EVMS researchers identify potential target for treatment of obesity-related diseases
Date:4/14/2010

Scientists from Eastern Virginia Medical School (EVMS) recently presented preliminary research findings that identify a specific gene as a potential new target for treating obesity-related diseases.

Two research studies funded by grants from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) examined the role of a gene called STAT4 in the development of Type 2 diabetes and other obesity-related cardiovascular diseases. The research was presented at the 2010 annual meeting of the American Heart Association's Council on Atherosclerosis, Thrombosis and Vascular Biology.

"We've known for some time that STAT4 is a 'gene switch,' meaning it is one of the genes that regulates or 'turns on' immune cells. But, our preliminary findings indicate that STAT4 is also involved in the metabolic process," says Anca D. Dobrian, PhD, assistant professor of physiology and lead author of one of the studies.

"Specifically, we've found that STAT4 appears to be involved in insulin resistance as well as the development of atherosclerosis," adds Elena V. Galkina, PhD, assistant professor of microbiology and molecular cell biology. "Assuming these results in rodent-models hold true for humans, STAT4 offers a potentially attractive target for therapy."

Early findings in these studies indicate that insulin resistance and atherosclerosis, a condition characterized by the thickening of artery walls due to fatty plaque deposits, occur in conjunction with elevated levels of STAT4.

The researchers learned that eliminating STAT4 in rodent models reduced the development of atherosclerosis. Similarly, eliminating STAT4 in rodent models given a high-fat diet revealed that while the rodents gained the same amount of weight as rodents with the gene, they did not develop insulin resistance which is a risk factor for Type 2 diabetes and other heart problems.

"Basically," says Jerry Nadler, MD, director of the
'/>"/>

Contact: Jina Gaines
gainesjn@evms.edu
757-446-7070
Eastern Virginia Medical School
Source:Eurekalert

Page: 1 2

Related biology news :

1. UI researchers analyze implications of intelligent design for human behavior
2. Stanford researchers find electrical current stemming from plants
3. UCLA researchers make first direct recording of mirror neurons in human brain
4. MIT researchers harness viruses to split water
5. Researchers use novel nanoparticle vaccine to cure type 1 diabetes in mice
6. Heinz Maier-Leibnitz Prizes 2010: 6 outstanding young researchers honored
7. Smart orthopedic implants and self-fitting tissue scaffolding created by UMMS researchers
8. Researchers find a better way to track stem cells
9. Researchers show some cells in pancreas can spontaneously change into insulin-producing cells
10. UMMS researchers uncover novel genetic pathway responsible for triggering vascular growth
11. Longer-lasting flowers: Fresh ideas from ARS researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... have discovered how two closely related proteins guide projections ... repelling these axons as they navigate the most miniscule ... remarkably precise connections. The discovery, reported April 28 ... belonging to the "semaphorin" family of guidance cues are ...
... As part of the Genome Canada Large-Scale Applied Research ... million to 16 projects across the country, the researchers ... function with the aim of identifying genes or proteins ... to target cancers and other diseases. The first ...
... by a parasitic fungus dramatically changes the behavior of tropical ... to become zombie-like and to die at a spot that ... team studied ants living high up in the rainforest canopy ... in the BioMed Central open-access journal BMC Ecology ...
Cached Biology News:Johns Hopkins scientists reveal nerve cells' navigation system 2Johns Hopkins scientists reveal nerve cells' navigation system 3OGI genomics researchers awarded $23 million 2OGI genomics researchers awarded $23 million 3Zombie ants have fungus on the brain, new research reveals 2
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
(Date:4/22/2015)... , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today ... first quarter 2015 on Thursday, May 7, 2015 after ... a webcast and conference call for 4.30 pm ET ... Live audio of the conference call will be ... investors, members of the news media and the general ...
(Date:4/22/2015)... Calif. , April 22, 2015 ... and analytics, announced today that it has opened ... its continued growth and expansion.  The common stock ... Act, Section 506(c), a law intended to encourage ... regulations.  Prior to 506(c), small businesses largely relied ...
(Date:4/22/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... to initiate a Phase 1 pharmacokinetic and biomarker ... Biohaven plans to initiate the trial no later ... in the Phase 1 study, Biohaven will move ...
Breaking Biology Technology:Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016 2Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016 3
... , , , , ... Inc.,(Nasdaq: SSRX ), a leading biotechnology company focused ... today announced that it has submitted its application for ... Drug,Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous,use. Feraheme ...
... , , ... enrollment of patients with acute ischemic stroke into its,Phase III ... at the Wolfson Medical Center, Israel. The MACSI trial involves,numerous ... Korea and Brazil. DP-b99 is D-Pharm,s most advanced product developed,for ...
... WASHINGTON, Dec. 29 The National Fragile X Foundation applauds ... Fragile X Syndrome for the first time ever within a ... U.S. Department of Defense. , The new law, ... through the FY 2010 Department of Defense Appropriations Act for ...
Cached Biology Technology:3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 33SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 4D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 3Defense Department to Support Fragile X Research 2